Akèy › Maladi Crohn › Maryland
Etid klinik pou Maladi Crohn nan Maryland
15 etid pou Maladi Crohn ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 85 · Tout sèks · Mizajou Oct 2, 2026 · NCT07619547A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Walter Reed National Military Medical Center ( Site 5006), Bethesda
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Capital Digestive Care, Chevy Chase
- Woodholme Gastroenterology, Glen Burnie
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Metropolitan Gastroenterology Group - Chevy Chase /ID# 265877, Chevy Chase
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates, Glen Burnie
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Capital Digestive Care - Chevy Chase, Chevy Chase
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Mercy Medical Center, Baltimore-Site Number: 8400117, Baltimore
- Mid-Atlantic GI Research, LLC-Site Number: 8400106, Laurel
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 18 a 65 · Tout sèks · Mizajou Aug 27, 2026 · NCT03167437Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Mercy Medical Center, Baltimore
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07237516Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- The Johns Hopkins Children's Medical Center, Baltimore
Ap rekriteFaz 4
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Woodholme Gastroenterology Associates, Glen Burnie
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou May 22, 2026 · NCT06764615A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Johns Hopkins University, Baltimore
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou May 5, 2026 · NCT04779320Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.